Paper Information

Title: 

CLINICAL VALUE OF BCL-2 ،CEA AND WITH GASTROINTESTINAL CANCERS

Type: PAPER
Author(s): REZAEI ABAS*,ANDALIB ALI REZA,SHOKOUHI R.
 
 *IMMUNOLOGY DEPARTMENT, ISFAHAN MEDICAL SCHOOL, ISFAHAN UNIVERSITY OF MEDICAL SCIENCES (IUMS), ISFAHAN, IRAN
 
Name of Seminar: BIENNIAL CONGRESS ON IMMUNOLOGY, ASTHMA AND ALLERGY
Type of Seminar:  CONGRESS
Sponsor:  IRAN UNIVERSITY OF MEDICAL SCIENCES AND HEALTH SERVICES
Date:  2007Volume 6
 
 
Abstract: 

Background: BCL-2 is an anti-apoptotic marker. The aim of the present study was to assess the serum level of BCL-2 in confirmed GI cancer patient, and compare the result with the two known tumor markers (i.e. CEA and CA19-9) in both case and control groups.
M&M: The groups including colon and gastric cancer patients and healthy matched individuals were undertaken. The peripheral blood was taken from GI cancer patient before operation, their sera were isolated, and the molecules markers were assessed using ELISA technique.
Results: The mean ± Std serum concentrations of BCL-2 was determined 8.48 ± 5.5ug/ml in gastric, 5.80±2.22 g/ml in colon, and 3.76±1.38
mg/ml in control groups. CEA was 54.47±23g/l, 52.95±22.5 g/l and 3.6±1.7 g/l in gastric, colon and healthy group respectively.CA19-9 was calculated 88.6± 96 U/ml, 79.47±0.95 U/ml and 14.6±9 /ml with above ordered, respectively. Correlation analysis indicates that the serum levels of these molecule markers are independent from each other (P>0.5).
Conclusion: While CEA and CA19-9 increased up to several folds in both gastric and colon cancer and indicated the status of malignancy in majority of cases, the alteration in BCL-2 serum levels could not be helpful to monitoring the patients. So our data did not support the Giannoulis et al (2004) and similar conclusion performance.

 
Keyword(s): 
 
Yearly Visit 4   tarjomyar
 
Latest on Blog
Enter SID Blog